373
Views
15
CrossRef citations to date
0
Altmetric
Review

A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer

, , &
Pages 1313-1328 | Published online: 11 Jun 2007

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Bengt Glimelius & Nina Cavalli-Björkman. (2012) Metastatic colorectal cancer: Current treatment and future options for improved survival Medical approach – present status . Scandinavian Journal of Gastroenterology 47:3, pages 296-314.
Read now

Articles from other publishers (14)

Takashi Morimoto, Kaori Fujito, Bumpei Yamasaki & Rei Goto. (2023) Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review. Clinical Therapeutics 45:1, pages 41-54.
Crossref
Ahmad Al Kadour, Wafa Al Marridi & Daoud Al-Badriyeh. (2018) Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality. Value in Health Regional Issues 16, pages 46-60.
Crossref
C.W.M. van Gils, S. de Groot, S.S. Tan, W.K. Redekop, M. Koopman, C.J.A. Punt & C.A. Uyl-de Groot. (2015) Real-world resource use and costs of adjuvant treatment for stage III colon cancer. European Journal of Cancer Care 24:3, pages 321-332.
Crossref
Nicolas Batty, Joseph Shatzel, Samuel Wiles, Mathew Kabalan, Rohit Sharma, Jonathan Pang, David Yi, Iris Alatovic, Sana Saif, Deepika Narasimha, Joseph LaPenna, Anthony Troitino, Kristopher Attwood, Michael Weinstein, Eric Murawski, Mathew Valerio, Yong Yin & Meir Wetzler. (2014) Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies. Journal of Cancer Policy 2:2, pages 40-44.
Crossref
A. Wuttke, K. C. Dixit, G. Szinnai, S. C. Werth, U. Haagen, M. Christ-Crain, N. Morgenthaler & G. Brabant. (2013) Copeptin as a marker for arginine-vasopressin/antidiuretic hormone secretion in the diagnosis of paraneoplastic syndrome of inappropriate ADH secretion. Endocrine 44:3, pages 744-749.
Crossref
Alan J. Ó Céilleachair, Paul Hanly, Máiréad Skally, Ciaran O’Neill, Patricia Fitzpatrick, Kanika Kapur, Anthony Staines & Linda Sharp. (2013) Cost Comparisons and Methodological Heterogeneity in Cost-of-illness Studies. Medical Care 51:4, pages 339-350.
Crossref
Livio Garattini, Katelijne van de Vooren & Alberto Zaniboni. (2013) Ethics for end-of-life treatments: Metastatic colorectal cancer is one example. Health Policy 109:1, pages 97-103.
Crossref
Arthi Vijayaraghavan, Molly B. Efrusy, Burkhard Göke, Thomas Kirchner, Christopher C. Santas & Richard M. Goldberg. (2012) Cost‐effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. International Journal of Cancer 131:2, pages 438-445.
Crossref
Jennifer G. Gaultney, W.K. Redekop, Pieter Sonneveld & Carin A. Uyl-de Groot. (2011) Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology. European Journal of Cancer 47:10, pages 1458-1467.
Crossref
David E. CohnKenneth H. KimKimberly E. ResnickDavid M. O'MalleyJ. Michael StraughnJrJr. (2011) At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis. Journal of Clinical Oncology 29:10, pages 1247-1251.
Crossref
Helena Linardou, Issa J Dahabreh, Dimitra Kanaloupiti, Fotios Siannis, Dimitrios Bafaloukos, Paris Kosmidis, Christos A Papadimitriou & Samuel Murray. (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. The Lancet Oncology 9:10, pages 962-972.
Crossref
T. YAU, P. CHAN, Y. Ching CHAN, B. C. Y. WONG, R. LIANG & R. J. EPSTEIN. (2008) Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies. Alimentary Pharmacology & Therapeutics 27:11, pages 997-1005.
Crossref
Javier Soto Álvarez. (2008) Necesidad de efectuar análisis de coste/efectividad para racionalizar y optimizar el gasto en nuevos medicamentos. Medicina Clínica 130:14, pages 559.
Crossref
A. Lansiaux. (2007) Quelles nouvelles à propos des antimétabolites en oncologie?What’s the news about antimetabolites in oncology?. Oncologie 9:11, pages 746-750.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.